Dihexa comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Bremelanotide was first developed by Palatin Technologies, then out-licensed to AMAG Pharmaceuticals Inc. after its approval by the FDA on 21 June 2019. Marked as VyleesiTM, it was primarily designed for both men and women in the form of an intranasal formulation, particularly for treating male erectile dysfunction. However, the research was discontinued and focused on targeting female HSDD in a subcutaneous injection to increase bioavailability. Bremelanotide is usually injected a minimum of 45 minutes before sexual activity. Despite having identical prescription criteria as that of flibanserin, bremelanotide is not recommended for pregnant patients. No trial was tested on pregnant patients. Therefore, patients at childbearing ages are recommended to use contraception continuously during treatment and should discontinue once they become pregnant.
Bottom photography as part of this project obtained images from the end of a film roll of a deep-sea camera sled (processed on board the vessel November 14, 1984) that resulted in clear images of vesicomyid clam chemosynthetic communities (Rossman et al., 1987) coincidentally in the same manner as the first documentation of chemosynthetic communities at the Galapagos Rift investigating hot water plumes by camera sled in the Pacific in 1976 (Lonsdale 1977). Photography during the same LGL/MMS cruise also documented tube-worm communities in situ in the Central Gulf of Mexico for the first time (not processed until after the cruise; Boland, 1986) prior to the initial submersible investigations and firsthand descriptions of Bush Hill (27°47′02″N 91°30′31″W) in 1986. The Bush Hill site was targeted by acoustic "wipeout" zones or lack of substrate structure caused by seeping hydrocarbons. This was determined using an acoustic pinger system during the same cruise on the R/V Edwin Link (renamed from Sea Diver and only 113 ft (34 m)), which used one of the Johnson Sea Link submersibles. This site represents the first eyes-on human observations of chemosynthetic communities in the northern Gulf of Mexico and is characterized by dense tubeworm and mussel accumulations, as well as exposed carbonate outcrops with numerous gorgonian and Lophelia coral colonies. Bush Hill has become one of the most thoroughly-studied chemosynthetic sites in the world.
== Formulations == The term dosage form may also sometimes refer only to the pharmaceutical formulation of a drug product's constituent substances, without considering its final configuration as a consumable product (e.g., capsule, patch, etc.). Due to the somewhat ambiguous nature and overlap of these terms within the pharmaceutical industry, caution is advisable when discussing them with others who may interpret the terminology differently.
== External links == MedlinePlus Encyclopedia: C-reactive protein Inflammation, Heart Disease and Stroke: The Role of C-Reactive Protein (American Heart Association) C-Reactive+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CRP: analyte monograph - The Association for Clinical Biochemistry and Laboratory Medicine George Vrousgos, N.D. - Southern Cross University Archived 2020-02-18 at the Wayback Machine Human CRP genome location and CRP gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P02741 (C-reactive protein) at the PDBe-KB.
Sources: en.wikipedia.org
== Processing == The first commercial process by which opiates are extracted from poppy straw was invented in Hungary by János Kabay. This process, known as the "poppy straw method", remains in use today. Kabay applied his new process initially to fields of opium poppies between the stages of flowering and maturity, while the fruits were green. This had several disadvantages: the immature poppy seeds could not be winnowed, so not only was the seed crop lost but their poppyseed oil interfered with the process; the abundant chlorophyll in the green plants also interfered; and an entire year's crop had to be processed in two months, as it reached the fruit stage. Kabay soon found that the process could be applied to poppy straw residue from the poppy seed harvest, thereby eliminating all these disadvantages. Poppy straw is first pulverized, then washed as many as six to ten or more times in water which may have an acid added to increase solubility, to produce poppy straw concentrate (PSC, also known as concentrate of poppy straw, CPS). Dried, the concentrate is a beige to brown powder. It contains salts of various alkaloids, and can range from nine to 30 times the morphine concentration of poppy straw. Opium concentrates using solvents other than acidifed or plain water are often but not necessarily called PSC. Poppies of the Norman and Przemko strains contain much higher amounts of thebaine (also known as paramorphine) and oripavine and have morphine concentrations from as low as below 1% up to 26% that of high-morphine strains.
Likewise, oral selegiline at an MAO-B-selective dosage did not appear to modify the pharmacodynamic effects or pharmacokinetics of intravenous methamphetamine in another study. Conversely, selegiline, also at MAO-B-selective doses, has been found to reduce the physiological and euphoric subjective effects of cocaine whilst not affecting its pharmacokinetics in some studies but not in others. Cautious safe combination of MAOIs like selegiline with stimulants like lisdexamfetamine has been reported. However, a hypertensive crisis with selegiline and ephedrine has also been reported. The selegiline drug labels warn about combination of selegiline with indirectly acting sympathomimetic agents, like amphetamines, ephedrine, pseudoephedrine, and phenylpropanolamine, due to the potential risk of hypertensive crisis, and recommend monitoring blood pressure with such combinations. The combination of selegiline with certain other medications, like phenylephrine and buspirone, is also warned against for similar reasons. In the case of phenylephrine, this drug is substantially metabolized by monoamine oxidase, including by both MAO-A and MAO-B. Selegiline can interact with exogenous dopamine, which is metabolized by MAO-A and MAO-B, and result in hypertensive crisis as well. Besides norepinephrine releasing agents, selective norepinephrine reuptake inhibitors (NRIs) may be safe in combination with MAOIs like selegiline. Potent NRIs, such as reboxetine, desipramine, protriptyline, and nortriptyline, can reduce or block the pressor effects of tyramine, including in those taking MAOIs.
9 May A record annual increase in atmospheric CO2 is reported from the Mauna Loa Observatory in Hawaii, with a jump of 4.7 parts per million (ppm) compared to a year earlier. A cubic millimetre of the human brain is mapped at nanoscale resolution by a team at Google. This contains roughly 57,000 cells and 150 million synapses, incorporating 1.4 petabytes of data. A study in Physical Review Letters concludes that the black hole in VFTS 243 likely formed instantaneously, with energy mainly expelled via neutrinos. This means it would have skipped the supernova stage entirely. An analysis of ocean protection for the global conservation target to protect at least 30% of the ocean by 2030 (30 by 30), finds around a quarter of marine protected area (MPA) coverage is not implemented, and one-third is incompatible with the conservation of nature due to the occurrence of highly destructive activities. According to the study, indicators of MPA quality, not only coverage, are needed. On 11 June, a study finds MPAs' effectiveness is not determined by any specific governance approaches or incentives, but the combination of many different integrated incentives. 10 May – A series of solar storms and intense solar flares impact the Earth, creating aurorae at more southerly and northerly latitudes than usual. 13 May – OpenAI reveals GPT-4o, its latest AI model, featuring improved multimodal capabilities in real time. 15 May Astronomers report an overview of preliminary analytical studies on returned samples of asteroid 101955 Bennu by the OSIRIS-REx mission.
== Other reactions == Ornithine, through the action of ornithine decarboxylase (EC 4.1.1.17), serves as the starting point for the synthesis of polyamines such as putrescine. In bacteria such as E. coli, ornithine can be synthesized from L-glutamate.
== Infection methods == Agrobacterium tumefaciens infects the plant through its Ti plasmid. The Ti plasmid integrates a segment of its DNA, known as T-DNA, into the chromosomal DNA of its host plant cells. A. tumefaciens has flagella that allow it to swim through the soil towards photoassimilates that accumulate in the rhizosphere around roots. Some strains may chemotactically move towards chemical exudates from plants, such as acetosyringone and sugars, which indicate the presence of a wound in the plant through which the bacteria may enter. Phenolic compounds are recognised by the VirA protein, a transmembrane protein encoded in the virA gene on the Ti plasmid. Sugars are recognised by the chvE protein, a chromosomal gene-encoded protein located in the periplasmic space. At least 25 vir genes on the Ti plasmid are necessary for tumor induction. In addition to their perception role, virA and chvE induce other vir genes. The VirA protein has autokinase activity: it phosphorylates itself on a histidine residue. Then the VirA protein phosphorylates the VirG protein on its aspartate residue. The virG protein is a cytoplasmic protein produced from the virG Ti plasmid gene. It is a transcription factor, inducing the transcription of the vir operons. The ChvE protein regulates the second mechanism of the vir genes' activation. It increases VirA protein sensitivity to phenolic compounds. Attachment is a two-step process.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.